Norepinephrine induced epithelial-mesenchymal transition in HT-29 and A549 cells in vitro

J Cancer Res Clin Oncol. 2016 Feb;142(2):423-35. doi: 10.1007/s00432-015-2044-9. Epub 2015 Sep 10.

Abstract

Purpose: Norepinephrine (NE) has been implicated in epithelial-mesenchymal transition (EMT) of cancer cells. However, the underlying mechanism is poorly understood. The goal of this study was to explore the effect of NE on cancer cell EMT and to investigate the potential mechanism.

Methods: HT-29 and A549 cells were treated with NE, β-adrenergic receptor (β-AR) antagonist (propranolol) or inhibitor of transforming growth factor-β (TGF-β) receptor type I kinase (Ly2157299). Morphology of cells was observed with optical and electron microscope and immunofluorescence staining. Cellular migration and invasion were tested with transwell migration assay and Matrigel invasion assay, respectively. TGF-β1 and cyclic adenosine monophosphate (cAMP) were quantified. EMT markers and signaling pathway were measured by RT-PCR and western blot.

Results: NE stimulated TGF-β1 secretion and intracellular cAMP synthesis, induced morphological alterations in HT-29 and A549 cells, and enhanced their ability of migration and invasion. EMT markers induction was observed in NE-treated cancer cells. The effect of NE could be inhibited by propranolol or Ly2157299. β-AR/TGF-β1 signaling/p-Smad3/Snail and β-AR/TGF-β1 signaling/HIF-1α/Snail were two signaling pathways.

Conclusion: These findings demonstrated that TGF-β1 signaling pathway was a significant factor of NE-induced cancer cells EMT. The data also suggested that psychological stress might be a risk factor which enhances the ability of migration or invasion of cancer cells.

Keywords: Adrenergic receptor; Chronic stress; Epithelial–mesenchymal transition; Norepinephrine; Transforming growth factor-β1.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adrenergic beta-Antagonists / pharmacology
  • Cell Line, Tumor
  • Cell Movement / drug effects
  • Colorectal Neoplasms / metabolism
  • Colorectal Neoplasms / pathology
  • Cyclic AMP / metabolism
  • Epithelial-Mesenchymal Transition / drug effects*
  • HT29 Cells
  • Humans
  • Lung Neoplasms / metabolism
  • Lung Neoplasms / pathology
  • Norepinephrine / pharmacology*
  • Propranolol / pharmacology
  • Pyrazoles / pharmacology
  • Quinolines / pharmacology
  • Transforming Growth Factor beta1 / antagonists & inhibitors
  • Transforming Growth Factor beta1 / metabolism

Substances

  • Adrenergic beta-Antagonists
  • Pyrazoles
  • Quinolines
  • Transforming Growth Factor beta1
  • LY-2157299
  • Propranolol
  • Cyclic AMP
  • Norepinephrine